Concepedia

James C. Stolzenbach

JC

Statistics

Publications

25

Citations

1.8K

H-Index

18

Active since

1991

Affiliations

Abbott (United States)(Current)

Baylor College of Medicine

Abbott Fund

University of Chicago

Icahn School of Medicine at Mount Sinai

James C. Stolzenbach is an author at Abbott (United States) specializing in pharmacology, clinical pharmacology, and pharmacy.

Publications per year

1991–2017

25

Publications

25

Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis

Edward Abraham, Konrad Reinhart, Steven M. Opal et al. · JAMA · 2003 · 957 citations

, , +15

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study

Peter H. Jones, Michael H. Davidson, Moti L. Kashyap et al. · Atherosclerosis · 2008 · 91 citations

, , +10

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study

Syed M. Mohiuddin, Carl J. Pepine, Maureen T. Kelly et al. · American Heart Journal · 2008 · 82 citations

, , +15

Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia

Anne C. Goldberg, Harold Bays, Christie M. Ballantyne et al. · The American Journal of Cardiology · 2008 · 67 citations

, , +14

Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy

Michael H. Davidson, Robert S. Rosenson, Kevin C. Maki et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2014 · 66 citations · Full text

, , +14

1–5 of 25